This week's genome editing triumph is a big deal.
Here's why
https://erictopol.substack.com/p/the-first-human-to-undergo-in-vivo

p-Tau217 is a breakthrough blood test that can predict and may help prevent Alzheimer's disease.
https://erictopol.substack.com/p/the-breakthrough-blood-test-for-alzheimers
Here's the rundown on it. Free, open-access.

Does the Shingles vaccine protect against dementia?https://erictopol.substack.com/p/the-shingles-vaccine-and-reduction

Excited to get a hold of my new book!

Only 9% of >105,000 people with 30-years of follow-up reached age 70 without chronic diseases.
Our diet and healthy aging, a review of the new report this week, and placing it in context
https://erictopol.substack.com/p/our-diet-and-healthy-aging

I've reviewed 10 consumer-facing companies that are in the business of promoting longevity and healthspan
https://erictopol.substack.com/p/the-business-of-promoting-longevity
Open-access, in the new edition of Ground Truths

Have a sweet tooth?
The basis may be in your gut.
https://erictopol.substack.com/p/how-our-gut-microbiome-can-drive

The scientist who is responsible for driving GLP-1 drugs for the treatment of obesity and testing them for prevention of Alzheimer's disease—Lotte Bjerre Knudsen— tells her story in a remarkable conversation. Full transcript, or video, all free, no ads.
https://erictopol.substack.com/p/lotte-bjerre-knudsen-the-scientist

A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated
https://www.nejm.org/doi/full/10.1056/NEJMoa2410819